Another myeloma drug with same target as CAR-Ts shows successful Phase II results

0
8


Without providing details, GlaxoSmithKline said its trial of BCMA-targeting belantamab mafodotin was positive. The company plans to submit for regulatory approvals later this year – potentially ahead of bluebird and Celgene’s expected filing next year for the CAR-T bb2121.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here